Brentuximab-vedotin and bendamustine produce long-term clinical benefit in patients with refractory or relapsed classical Hodgkin lymphoma: a multicenter real-life experience

Patients with relapsed or refractory classical Hodgkin lymphoma (R/RcHL) have limited opportunities for a curative therapy. High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT) produces cure rates of 50-60%. Patients relapsing after, or ineligible for HDT-ASCT have limited therapeutic options and long-term remission is uncommon. Furthermore, few patients are candidate to allogeneic stem cell transplantation (AlSCT), a potentially curative approach. The combination of brentuximab-vedotin and bendamustine (BVB) is a promising treatment for patients with R/RcHL, regardless of SCT eligibility.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 29, 2021 Category: Hematology Authors: Marina Moretti, Anna Marina Liberati, Luigi Rigacci, Benedetta Puccini, Alessandro Pulsoni, Guido Gini, Piero Galieni, Alberto Fabbri, Maria Cantonetti, Vincenzo Pavone, Silvia Bolis, Barbara Botto, Daniela Renzi, Lorenzo Falchi Tags: Original article Source Type: research